Myeloid and Monocytic Leukemia, Phase I

A Phase 1 Study of ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies.

Volunteers
Health Professionals

What is the purpose of this trial?

Evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ICP-248 in combination with azacitidine in patients with acute myelogenous leukemia and Myelodysplastic Syndromes.

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Farah Fasihuddin

farah.fasihuddin@yale.edu

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Amer Zeidan, MBBS, MD
Professor of Internal Medicine (Hematology); Chief, Division of Hematologic Malignancies; Director, Early Therapeutics Research, Yale Cancer Center; Director, Leukemia and Myeloid Malignancies Program, Yale Cancer Center; Assistant Medical Director, Clinical Trials Office (CTO), Yale Cancer Center; Co-Leader, Leukemia and Myeloid Malignancies Clinical Research Team (CRT), Yale Cancer Center

Sub-Investigators

Last Updated
04/30/2026
Study IRB
#2000040333